Clinical Trials Show Efficacy and Safety of Upadacitinib for Vitiligo

New research published in The Lancet details the positive results from two Phase 3 clinical trials, Viti-Up, evaluating upadacitinib. These studies demonstrated the efficacy and safety of the drug for treating non-segmental vitiligo in both adults and adolescents. The findings are significant for a condition that impacts many individuals, potentially advancing treatment options.